IL131238A - Pharmaceutical composition of hedgehog protein and use thereof - Google Patents

Pharmaceutical composition of hedgehog protein and use thereof

Info

Publication number
IL131238A
IL131238A IL13123899A IL13123899A IL131238A IL 131238 A IL131238 A IL 131238A IL 13123899 A IL13123899 A IL 13123899A IL 13123899 A IL13123899 A IL 13123899A IL 131238 A IL131238 A IL 131238A
Authority
IL
Israel
Prior art keywords
hedgehog protein
pharmaceutical composition
ions
composition
cyclodextrin
Prior art date
Application number
IL13123899A
Other languages
English (en)
Other versions
IL131238A0 (en
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98114851A external-priority patent/EP0987028A1/de
Application filed by Curis Inc filed Critical Curis Inc
Publication of IL131238A0 publication Critical patent/IL131238A0/xx
Publication of IL131238A publication Critical patent/IL131238A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL13123899A 1998-08-07 1999-08-04 Pharmaceutical composition of hedgehog protein and use thereof IL131238A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98114851A EP0987028A1 (de) 1998-08-07 1998-08-07 Pharmazeutische Zusammensetzung von Hedgehog-Proteinen und deren Verwendung
EP98116734 1998-09-03

Publications (2)

Publication Number Publication Date
IL131238A0 IL131238A0 (en) 2001-01-28
IL131238A true IL131238A (en) 2005-07-25

Family

ID=26149508

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13123899A IL131238A (en) 1998-08-07 1999-08-04 Pharmaceutical composition of hedgehog protein and use thereof

Country Status (15)

Country Link
US (1) US6207718B1 (no)
EP (1) EP0978285B1 (no)
JP (1) JP3567103B2 (no)
CN (1) CN1244429A (no)
AT (1) ATE310531T1 (no)
AU (1) AU761341B2 (no)
CA (1) CA2279743C (no)
DE (1) DE69928472T2 (no)
DK (1) DK0978285T3 (no)
ES (1) ES2253851T3 (no)
HK (1) HK1025740A1 (no)
HU (1) HUP9902655A3 (no)
IL (1) IL131238A (no)
MA (1) MA26667A1 (no)
NO (1) NO993804L (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2312009A1 (en) * 1997-11-28 1999-06-10 Roche Diagnostics Gmbh An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
US6897297B1 (en) * 1997-12-03 2005-05-24 Curis, Inc. Hydrophobically-modified protein compositions and methods
ATE308563T1 (de) * 1998-04-30 2005-11-15 Curis Inc Aktives hedgehog-protein-konjugat, verfahren zur herstellung und verwendung
EP1025861A1 (de) * 1999-02-04 2000-08-09 Roche Diagnostics GmbH Pharmazeutische Zusammensetzung von hydrophob modifizierten Hedgehog-Proteinen und deren Verwendung
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
CA2280925A1 (en) * 1999-07-29 2001-01-29 Bernard Charles Sherman Stabilized cefuroxime axetil
US7052514B2 (en) 2000-04-28 2006-05-30 Curis, Inc. Methods and reagents for tissue engineering of cartilage in vitro
EP1947116B1 (en) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
US20070053883A1 (en) * 2003-03-25 2007-03-08 The Johns Hopkins University Neuronal cell lineages and methods of production thereof
US20070148144A1 (en) * 2005-10-27 2007-06-28 Mason James M Gene-enhanced tissue engineering
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
SI2308514T1 (sl) 2007-03-23 2013-09-30 To-Bbb Holding B.V. Konjugati za prenos zdravila preko krvno-moĹľganske pregrade
US7678764B2 (en) * 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CA2692231A1 (en) * 2007-06-29 2009-01-08 Advanced Technologies And Regenerative Medicine, Llc Liquid protein formulations comprising gdf-5 for use at elevated temperatures
US8058237B2 (en) * 2007-08-07 2011-11-15 Advanced Technologies & Regenerative Medicine, LLC Stable composition of GDF-5 and method of storage
EP2276458A1 (en) * 2008-04-14 2011-01-26 Advanced Technologies and Regenerative Medicine, LLC Liquid buffered gdf-5 formulations
WO2010087702A1 (en) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
JP2013505232A (ja) 2009-09-16 2013-02-14 スティヒティング ヘット ネーデルラント カンカー インスティテュート 癌治療のための薬剤標的としてのＦｒａ−１標的遺伝子
EP2305717A1 (en) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Inhibiting TNIK for treating colon cancer
BR112013004389A2 (pt) 2010-08-27 2016-05-17 Pantarhei Bioscience Bv método imunoterapêutico para tratamento do câncer de próstata
EP2465928A1 (en) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Treatment of Th17-mediated diseases
WO2015070031A1 (en) 2013-11-08 2015-05-14 University Of Virginia Patent Foundation Compositions and methods for treating melanoma
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
CA3043886A1 (en) * 2016-11-16 2018-05-24 Aivita Biomedical, Inc. Use of cell membrane-bound signaling factors
WO2019099861A1 (en) * 2017-11-16 2019-05-23 Aivita Biomedical, Inc. Use of cell membrane-bound signaling factors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148901A (en) 1983-10-04 1985-06-05 Johnson & Johnson Protein/polysaccharide complexes
JPH0725689B2 (ja) 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5156623A (en) 1990-04-16 1992-10-20 Olympus Optical Co., Ltd. Sustained release material and method of manufacturing the same
US5416071A (en) 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5789543A (en) 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
CA2179029C (en) * 1993-12-30 2009-02-24 Philip W. Ingham Vertebrate embryonic pattern-inducing hedgehog-like proteins
EP0773995A4 (en) 1994-02-25 1997-07-16 Univ Columbia DNA ENCODING THE HEDGEHOG'S VERBLE ANIMAL HOMOLOGIST, VHH-1, EXPRESSED IN NOTOCHORD AND ITS USE
US5663390A (en) 1996-08-29 1997-09-02 Libbey-Owens-Ford Co. Method of producing organo indium chlorides
JPH10194987A (ja) 1997-01-14 1998-07-28 Youtai Iwamoto 骨・軟骨形成用組成物
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
EP0947201B1 (en) * 1998-02-04 2006-06-28 Curis, Inc. Pharmaceutical composition of hedgehog proteins and use thereof
EP0953575A1 (de) * 1998-04-30 1999-11-03 Boehringer Mannheim Gmbh Aktives Hedgehog-Protein-Konjugat, Verfahren zur Herstellung und Verwendung
ATE308563T1 (de) * 1998-04-30 2005-11-15 Curis Inc Aktives hedgehog-protein-konjugat, verfahren zur herstellung und verwendung

Also Published As

Publication number Publication date
HU9902655D0 (en) 1999-10-28
IL131238A0 (en) 2001-01-28
US6207718B1 (en) 2001-03-27
DE69928472D1 (de) 2005-12-29
JP2000063283A (ja) 2000-02-29
HUP9902655A3 (en) 2000-12-28
ES2253851T3 (es) 2006-06-01
AU761341B2 (en) 2003-06-05
CA2279743C (en) 2005-05-10
NO993804L (no) 2000-02-08
HK1025740A1 (en) 2000-11-24
MA26667A1 (fr) 2004-12-20
EP0978285A1 (en) 2000-02-09
ATE310531T1 (de) 2005-12-15
CN1244429A (zh) 2000-02-16
HUP9902655A2 (hu) 2000-08-28
NO993804D0 (no) 1999-08-06
EP0978285B1 (en) 2005-11-23
DE69928472T2 (de) 2006-08-10
AU4344899A (en) 2000-03-02
CA2279743A1 (en) 2000-02-07
DK0978285T3 (da) 2006-03-27
JP3567103B2 (ja) 2004-09-22

Similar Documents

Publication Publication Date Title
IL131238A (en) Pharmaceutical composition of hedgehog protein and use thereof
ATE409496T1 (de) Hautdesodorierende und desinfizierende zubereitung
AU1870099A (en) Stabilised insulin compositions
UA34466C2 (uk) Засіб для несистемної боротьби з паразитуючими комахами
AU2339699A (en) Aqueous metal treatment composition
AU3510500A (en) Fragrance and flavor compositions containing odor neutralizing agents
AU1918800A (en) Skin deodorizing and sanitizing compositions
AU1827600A (en) Non-corrosive sterilant composition
RS50071B (sr) Novi oblik soli pantoprazola
DE69801577D1 (de) Staubkontrollzusammensetzung
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
BR0009502A (pt) Componente de amaciamento de tecido
HUP0401583A2 (hu) Látens savanyítószert tartalmazó toalett szappan
GB0027405D0 (en) Composition
TR199903132A3 (tr) Metalosan bilesiklerinin aktive edici kompozisyonu.
AU3835399A (en) Perfume composition
AU2003201721A1 (en) Aqueous odor control composition
AU8884298A (en) Deodorant compositions and method
AU5011396A (en) Surfactant compositions with anti-microbial effect
AU2035700A (en) Odor eliminating aqueous formulation
BR0009469A (pt) Tablete perfumado de detergente
BR9916537B1 (pt) composição de fragráncia, e, produto.
AU2002215787A1 (en) Odor control agent
AU2001265876A1 (en) Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases
WO2004112843A3 (en) Odor control compositions and methods

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees